We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01349660
Recruitment Status : Active, not recruiting
First Posted : May 6, 2011
Last Update Posted : October 5, 2017
Information provided by (Responsible Party):

Study Description
Brief Summary:
In this phase I/II study,investigators are evaluating the feasibility and efficacy of the combination of BKM120, an oral inhibitor of PI3 kinase, and bevacizumab in the treatment of patients with relapsed/refractory GBM. In the Phase I part of the trial, the optimal BKM120 dose to be administered with a standard dose of bevacizumab will be determined in patients with refractory solid tumors. Although it is unlikely that the concurrent administration of bevacizumab will alter the pharmacokinetics of BKM120, limited pharmacokinetic sampling will be performed on all patients treated during the Phase II portion of the study. Assuming this combination is feasible, the Phase II portion of the study will proceed, using the doses determined in the Phase I portion. In the phase II portion, eligible patients will be limited to those with recurrent/progressive GBM following 1st line combined modality therapy.

Condition or disease Intervention/treatment Phase
Glioblastoma Multiforme Drug: Bevacizumab Drug: BKM120 Phase 1 Phase 2

Detailed Description:

This is an open-label, non-randomized Phase I study of patients with advanced refractory solid tumors followed by a Phase II study for the second-line treatment of patients with relapsed/refractory glioblastoma multiforme.

In the phase I part of the study the MTD of BKM120 when combined with bevacizumab was determined to be 60 mg/day. In the Phase II part of this study, patients with relapsed/refractory GBM following first line therapy are being treated with the BKM120/bevacizumab combination. Limited BKM120 pharmacokinetic evaluation will be performed on all patients treated during this part of the study. Patients will be reevaluated for response to treatment after 2 cycles (8 weeks). Patients with objective response or stable disease will continue treatment, with subsequent reevaluations every 8 weeks, until disease progression or unacceptable toxicity occurs.

Two populations of patients with relapsed/refractory GBM will be treated in the Phase II trial: 1) patients with no previous exposure to bevacizumab (N= 55) and 2) patients who received bevacizumab as part of first-line combined modality treatment (N= 20).

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 88 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I/II Study of the Combination of BKM120 and Bevacizumab in Patients With Refractory Solid Tumors (Phase I) and Relapsed/Refractory Glioblastoma Multiforme (Phase II)
Study Start Date : December 2011
Primary Completion Date : December 2016
Estimated Study Completion Date : February 2018

Resource links provided by the National Library of Medicine

Drug Information available for: Bevacizumab
U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Experimental: BKM120/Bevacizumab

Phase I:

BKM 120 orally (PO) once daily (dose to be determined) Bevacizumab: 10mg/kg intravenous (IV) every 2 weeks

Phase II:

BKM 120 orally (PO) once daily - 60mg was the maximum tolerated dose (MTD) determined in Phase I Bevacizumab: 10mg/kg intravenous (IV) every 2 weeks

Drug: Bevacizumab
Bevacizumab 10 mg/kg IV every 2 weeks
Other Name: Avastin
Drug: BKM120
BKM120 orally (PO) once daily
Other Name: Buparlisib

Outcome Measures

Primary Outcome Measures :
  1. Number of patients experiencing a dose-limiting toxicity (DLT) as a Measure of Safety and Tolerability [ Time Frame: 18 months ]
    Phase 1: The optimal dose of BKM120 to administer in combination with standard dose bevacizumab determined as the highest dose at which ≤1 of 6 patients experiences a DLT assessed using NCI CTCAE v4.0.

  2. Median Progression-Free Survival [ Time Frame: every 8 weeks, estimated 24 months ]
    Phase 2: Measured from the date of first protocol treatment until date of tumor progression or death occurs, or date of last adequate tumor assessment analyzed using Kaplan-Meier methods..

Secondary Outcome Measures :
  1. Frequency and severity of adverse events as a measure of toxicity. [ Time Frame: every 8 weeks, projected 24 months ]
    Safety will be evaluated for patients in Phase I and II based on NCI CTCAE v4.0 criteria.

  2. Overall Survival (OS) [ Time Frame: every 8 weeks, projected 24 months ]
    Measured as the interval from first study treatment until date of death, or date last known alive.

  3. Overall Response Rate [ Time Frame: every 8 weeks, projected 24 months ]
    Proportion of patients with confirmed complete or partial responses (CR or PR) according to RECIST v1.1 criteria.

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Phase I ONLY:

  • Advanced, metastatic solid tumor that has progressed after standard therapy, or is a tumor type resistant to therapy, and for which bevacizumab is clinically appropriate.
  • Patient may have measurable disease or non-measureable disease as defined by RECIST v1.1 criteria

Phase II ONLY:

  • Progressive GBM after treatment with surgical resection (if possible) and 1st line radiation/chemotherapy.
  • No previous treatment with a PI3K inhibitor. Previous treatment with bevacizumab as a component of first-line therapy is allowed.
  • At least one measurable or evaluable lesion definable by MRI scan. Disease must be measurable by RANO criteria.
  • Archival tumor tissue available for correlative testing.


  • Patient must be ≥ 4 weeks from administration of last dose of cancer therapy (including radiation therapy, biologic therapy, hormonal therapy, or chemotherapy). Patients who receive a small molecule targeted therapy as part of their first line treatment regimen must be ≥ 4 weeks or ≥ 5 half lives from administration of last dose, whichever is shorter. The patient must have recovered from or come to a new chronic or stable baseline from all treatment-related toxicities.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
  • Life expectancy of ≥ 3 months.
  • Adequate hematologic, hepatic, and renal function.

Exclusion Criteria:

  • Patients with diarrhea ≥ grade 2.
  • Patients with uncontrolled type I or type II diabetes mellitus, defined as a fasting plasma glucose ≥120 mg/dL.
  • Patients who have received prior treatment with a P13K inhibitor.
  • Treatment with therapeutic doses of coumarin-type anticoagulants (maximum daily dose of 1 mg allowed for port line patency permitted).
  • Patient has active cardiac disease including any of the following:

    • Left ventricular ejection fraction (LVEF) < 50% as determined by Multiple Grated acquisition (MUGA) scan or echocardiogram (ECHO)
    • QTc > 480 msec on screening ECG (using the QTcF formula)
    • Angina pectoris that requires the use of anti-anginal medication
    • Ventricular arrhythmias except for benign premature ventricular contractions
    • Supraventricular and nodal arrhythmias requiring a pacemaker or not controlled with medication
    • Conduction abnormality requiring a pacemaker
    • Valvular disease with documented compromise in cardiac function
    • Symptomatic pericarditis
  • Patients who are currently receiving treatment with medication with a known risk to prolong the QT interval or inducing Torsades de Pointes and the treatment cannot either be discontinued or switched to a different medication prior to starting study drug.
  • Patients with clinical history of hemoptysis or hematemesis (defined as having bright red blood of ½ teaspoon or more per episode) ≤1 month prior to study enrollment.
  • Patients with any history of a bleeding diathesis or coagulopathy (in the absence of therapeutic anticoagulation)
  • Patients who have received chemotherapy or targeted anticancer therapy ≤ 4 weeks (6 weeks for nitrosourea, antibodies or mitomycin-C) prior to starting study drug must recover to a grade 1 before starting the trial.
  • Patients who have received any continuous or intermittent small molecule therapeutics (excluding monoclonal antibodies) ≤ 5 effective half lives prior to starting study drug or who have not recovered from side effects of such therapy.
  • Patients who have been treated with any hematopoietic colony-stimulating factors (e.g. G-CSF, GM-CSF) ≤ 2 weeks prior to starting study drug. Erythropoietin or darbepoetin therapy, if initiated at least 2 weeks prior to enrollment may be continued.
  • Major surgical procedure, open biopsy, intracranial biopsy, ventriculoperitoneal shunt or significant traumatic injury ≤ 28 days prior to entry.
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01349660

United States, Connecticut
Yale School of Medicine
New Haven, Connecticut, United States, 06520
United States, Florida
Florida Cancer Specialists
Fort Myers, Florida, United States, 33916
Florida Hospital Cancer Institute
Orlando, Florida, United States, 32804
Florida Cancer Specialists
Saint Petersburg, Florida, United States, 33705
United States, Maryland
Center for Cancer and Blood Disorders
Bethesda, Maryland, United States, 20817
United States, Michigan
Grand Rapids Oncology Program
Grand Rapids, Michigan, United States, 49503
United States, Nebraska
Nebraska Methodist Hospital
Omaha, Nebraska, United States, 68114
United States, Tennessee
Tennessee Oncology
Nashville, Tennessee, United States, 37203
Sponsors and Collaborators
SCRI Development Innovations, LLC
Study Chair: John Hainsworth, MD SCRI Development Innovations, LLC
More Information

Responsible Party: SCRI Development Innovations, LLC
ClinicalTrials.gov Identifier: NCT01349660     History of Changes
Other Study ID Numbers: SCRI CNS 13
First Posted: May 6, 2011    Key Record Dates
Last Update Posted: October 5, 2017
Last Verified: October 2017

Keywords provided by SCRI Development Innovations, LLC:
Glioblastoma multiforme
PI3K Pathway

Additional relevant MeSH terms:
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents